Compare SGP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGP | VALN |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | France |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 650.9M | 536.9M |
| IPO Year | N/A | 2021 |
| Metric | SGP | VALN |
|---|---|---|
| Price | $18.67 | $5.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $45.00 | $15.50 |
| AVG Volume (30 Days) | ★ 41.0K | 38.1K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.60 | $5.06 |
| 52 Week High | $30.56 | $12.25 |
| Indicator | SGP | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 39.25 |
| Support Level | N/A | $5.11 |
| Resistance Level | $26.29 | $6.60 |
| Average True Range (ATR) | 1.52 | 0.27 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 20.34 | 5.26 |
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.